⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244348 | 0.93 | — | — | |
| SCHEMBL19066054 | 0.90 | CA1 (0.52) | — | |
| SCHEMBL21943788 | 0.90 | CA1 (0.52) | — | |
| Hydrochloric Acid SCHEMBL29086421 | 0.90 | APLNR (0.52) | — | |
| SCHEMBL393197 | 0.90 | CA1 (0.52) | — | |
| SCHEMBL1648801 | 0.90 | CA1 (0.52) | — | |
| SCHEMBL1649129 | 0.90 | CA1 (0.52) | — | |
| SCHEMBL14462832 | 0.90 | CA1 (0.52) | — | |
| SCHEMBL19479300 | 0.90 | CA1 (0.52) | — | |
| Hydrochloric Acid SCHEMBL21598754 | 0.88 | CA1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 640 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | claimed |
| CN-115632107-A | Carbon-coated lithium iron phosphate electrode modified by organic coating, preparation method thereof and lithium ion battery | 江苏中兴派能电池有限公司 | 2023-01-20 | — | — | CN | claimed |
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2022-10-18 | — | — | US | claimed |
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| CN-109251588-A | Inorganic nano material ink and its preparation method and application, QLED device | TCL集团股份有限公司 | 2019-01-22 | — | — | CN | claimed |
| CN-105008362-B | Pyrrolo [2,3-D ] pyrimidine derivatives as janus-related kinase (JAK) inhibitors | 辉瑞大药厂 | 2017-06-06 | — | — | CN | claimed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | claimed |
| US-7244692-B2 | Substituted benzoylcyclohexane diones for use as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2007-07-17 | — | — | US | claimed |
| CN-1832929-A | 2, 4-pyrimidinediamines for the treatment of neoplastic diseases, inflammatory diseases and immune system disorders | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | claimed |
| US-20050054534-A1 | Substituted benzoylcyclohexane diones for use as herbicides | MULLER KLAUS-HELMUT (DE) | 2005-03-10 | — | — | US | claimed |
| EP-0906291-B1 | SUBSTITUTED PHENYL URACILS | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | claimed |
| US-6825183-B2 | CONTROLLING PLANTS; ANTIGROWTH AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-30 | — | — | US | claimed |
| EP-1244634-B1 | SUBSTITUTED BENZOYLCYCLOHEXANE DIONES FOR USE AS HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2004-03-17 | — | — | EP | claimed |
| US-20030119674-A1 | Substituted benzoylcyclohexane diones for use as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-26 | — | — | US | claimed |
| EP-1244634-A1 | SUBSTITUTED BENZOYLCYCLOHEXANE DIONES FOR USE AS HERBICIDES | BAYER AG (DE) | 2002-10-02 | — | — | EP | claimed |
| WO-2001047894-A1 | SUBSTITUTED BENZOYLCYCLOHEXANE DIONES FOR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | claimed |
| US-6245714-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | claimed |
| EP-0906291-A1 | SUBSTITUTED PHENYL URACILS | BAYER AG (DE) | 1999-04-07 | — | — | EP | claimed |
| WO-1997045418-A1 | SUBSTITUTED PHENYL URACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-04 | — | — | WO | claimed |
| CN-122080012-A | Thienopyrimidine derivative, preparation method, application and pharmaceutical composition thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4263518-B1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12570615-B2 | Quinazolinone derivatives | HOFFMANN-LA ROCHE INC. | 2026-03-10 | — | — | US | disclosed |
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2025-12-23 | — | — | US | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250270180-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | IMMUNEERING CORPORATION | 2025-08-28 | — | — | US | disclosed |
| US-12351566-B2 | MEK inhibitors and therapeutic uses thereof | IMMUNEERING CORPORATION (US) | 2025-07-08 | — | — | US | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025096858-A1 | COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12281125-B2 | Rapamycin derivatives | NOVARTIS AG (CH) | 2025-04-22 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025054459-A1 | RNAI OLIGONUCLEOTIDE CONJUGATES | DICERNA PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-113490668-B | Compounds and compositions for the treatment of diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119487021-A | Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK) | 内斯特治疗公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-119219809-A | Fluorine-containing polymer, preparation method thereof and ion exchange membrane | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-3898637-B1 | RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2024-11-20 | — | — | EP | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-4364798-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | Annapurna Bio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117956992-A | MENIN-MLL interaction inhibitors | 赛达克斯制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3395583-B1 | HEAT-SENSITIVE RECORDING MATERIAL | NIPPON KAYAKU KK (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-113226310-B | 15-PGDH inhibitors | 杏林制药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| CN-117693500-A | Carboxamide derivative and agricultural/horticultural plant disease control agent | 组合化学工业株式会社 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20240010645-A1 | Aminothiazole Compounds as Inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2024-01-11 | — | — | US | disclosed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| US-11802208-B2 | Stilbene-based compound or salt thereof, and polarizing film, polarizing plate, and display device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4263518-A1 | NEW QUINAZOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116601147-A | Novel quinazolinone derivatives | 豪夫迈·罗氏有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230197934-A1 | CATHODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | SK ON CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| WO-2023112856-A1 | FUSED HETEROCYCLIC DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | クミアイ化学工業株式会社 | 2023-06-22 | — | — | WO | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| CN-116034036-A | Thermosensitive recording material | 日本化药株式会社 | 2023-04-28 | — | — | CN | disclosed |
| US-20230119327-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | IMMUNEERING CORPORTAION | 2023-04-20 | — | — | US | disclosed |
| CN-111435705-B | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230082516-A1 | 15-PGDH INHIBITOR | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-16 | — | — | US | disclosed |
| CN-115632107-A | Carbon-coated lithium iron phosphate electrode modified by organic coating, preparation method thereof and lithium ion battery | 江苏中兴派能电池有限公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2023286855-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | クミアイ化学工業株式会社 | 2023-01-19 | — | — | WO | disclosed |
| US-20230019461-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022257047-A1 | DIAZASPIROBICYLIC COMPOUNDS AS PROTEIN-PROTEIN INTERACTION INHIBITORS AND APPLICATIONS THEREOF | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4087840-A1 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | Immuneering Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
| CN-115151533-A | MEK inhibitors and therapeutic uses thereof | 医疗免疫工程公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| CN-110945083-B | Styrene compound or salt thereof, polarizing film, polarizing plate and display device | 日本化药株式会社 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022129259-A1 | NEW QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129259-A1 | NEW QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-23 | — | — | WO | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| EP-4006028-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | Zhuhai Yufan Biotechnologies Co., Ltd (CN) | 2022-06-01 | — | — | EP | disclosed |
| EP-3998502-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220064185-A1 | RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2022-03-03 | — | — | US | disclosed |
| CN-114026199-A | Polarizing luminescent film, polarizing luminescent sheet, and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3922247-A1 | 15-PGDH INHIBITOR | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-15 | — | — | EP | disclosed |
| EP-3917911-A1 | 15-PGDH INHIBITORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3914583-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| EP-3898637-A1 | RAPAMYCIN DERIVATIVES | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113490668-A | Compounds and compositions for treating diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| CN-113316566-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-113260619-A | Rapamycin derivatives | 诺华股份有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3860998-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | Annapurna Bio Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113226310-A | 15-PGDH inhibitors | 杏林制药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| CN-105153014-B | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | 安姆根有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-107848962-B | Urea derivative or pharmacologically acceptable salt thereof | 杏林制药株式会社 | 2021-04-09 | — | — | CN | disclosed |
| WO-2021018012-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | 珠海宇繁生物科技有限责任公司 | 2021-02-04 | — | — | WO | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3733670-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Mediconns (Shanghai) Biopharmaceutical Co., Ltd (CN) | 2020-11-04 | — | — | EP | disclosed |
| EP-3717459-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
| US-10780724-B2 | Heat-sensitive recording material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-09-22 | — | — | US | disclosed |
| WO-2020160151-A1 | 15-PGDH INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020154321-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020145250-A1 | 15-PGDH INHIBITOR | 杏林製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020128861-A1 | RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3660106-A1 | STILBENE COMPOUND OR SALT THEREOF, POLARIZING FILM, POLARIZING PLATE AND DISPLAY DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20200157353-A1 | STILBENE-BASED COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE, AND DISPLAY DEVICE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| WO-2020073011-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020073011-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| CN-108430789-B | Thermosensitive recording material | 日本化药株式会社 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945083-A | Styrene compound or salt thereof, polarizing film, polarizing plate and display device | 日本化药株式会社 | 2020-03-31 | — | — | CN | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10343438-B2 | Heat-sensitive recording material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-07-09 | — | — | US | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3483143-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-109251588-A | Inorganic nano material ink and its preparation method and application, QLED device | TCL集团股份有限公司 | 2019-01-22 | — | — | CN | disclosed |
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| CN-106748814-B | N- cyclic amides as nematicide | 先正达参股股份有限公司 | 2018-12-14 | — | — | CN | disclosed |
| US-20180345710-A1 | Heat-Sensitive Recording Material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2018-12-06 | — | — | US | disclosed |
| EP-3395583-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Nippon Kayaku Kabushiki Kaisha (JP) | 2018-10-31 | — | — | EP | disclosed |
| CN-104370909-B | Tricyclic compound | ABBVIE 公司 | 2018-09-11 | — | — | CN | disclosed |
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3150600-B1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | QILU PHARMACEUTICAL CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| EP-3303284-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170297355-A1 | Heat-Sensitive Recording Material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3107920-B1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | Bayer Pharma AG (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170273978-A1 | IMIDAZOYL ANILIDE DERIVATIVES AND METHODS OF USE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-09-28 | — | — | US | disclosed |
| US-20170273978-A1 | IMIDAZOYL ANILIDE DERIVATIVES AND METHODS OF USE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-09-28 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| CN-106748814-A | As the N cyclic amides of nematicide | 先正达参股股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| CN-104203916-B | N-cyclic amides as nematicides | 先正达参股股份有限公司 | 2017-05-03 | — | — | CN | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3150600-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | Medshine Discovery Inc. (CN) | 2017-04-05 | — | — | EP | disclosed |
| US-9593129-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| CN-106459090-A | 3-(pyrimidine-2-yl)imidazo[1,2-A]pyridines | 拜耳制药股份公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9562052-B2 | Bicyclicpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3107920-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-28 | — | — | EP | disclosed |
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| CN-103906735-B | Novel aryl-quinoline derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-07 | — | — | CN | disclosed |
| WO-2016189877-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | WO | disclosed |
| US-20160347770-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9499550-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2773619-B1 | NEW ARYL-QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| EP-3085695-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | disclosed |
| EP-2705049-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2888245-B1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-09-21 | — | — | EP | disclosed |
| CN-105906535-A | Safener for protecting crops from phytotoxicity of herbicide, combination agent and use method | 沈阳农业大学 | 2016-08-31 | — | — | CN | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-9414589-B2 | N-cyclylamides as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-16 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| EP-2831046-B1 | N-CYCLYLAMIDES AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9296736-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| EP-2606038-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150368256-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2951170-A2 | FLAP MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2015-12-09 | — | — | EP | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150315146-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYLETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| EP-2049474-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2049474-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2928297-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-20150284391-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| EP-2927213-A1 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | Amgen Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2086963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2086963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| CN-104918941-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-09-16 | — | — | CN | disclosed |
| WO-2015124544-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | WO | disclosed |
| EP-2909205-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| CN-102971291-B | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2015-07-22 | — | — | CN | disclosed |
| EP-2888245-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2300490-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2300490-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8957203-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-17 | — | — | US | disclosed |
| US-20150045213-A1 | N-CYCLYLAMIDES AS NEMATICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2831046-A1 | N-CYCLYLAMIDES AS NEMATICIDES | Syngenta Participations AG (CH) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2183252-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| CN-104203916-A | N-cyclic amides as nematicides | SYNGENTA PARTICIPATIONS AG | 2014-12-10 | — | — | CN | disclosed |
| EP-2086994-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| CN-102239152-B | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP. (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2773619-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8816079-B2 | Amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| WO-2014121055-A2 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | WO | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| CN-103906735-A | Novel aryl-quinoline derivatives | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | disclosed |
| US-8765944-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086723-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| US-8710229-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2014062196-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-1684787-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1684787-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1951743-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-1951743-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-1945641-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-1945641-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2705049-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2014029723-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-13 | — | — | US | disclosed |
| CN-102112486-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-02-12 | — | — | CN | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013143811-A1 | N-CYCLYLAMIDES AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-03 | — | — | WO | disclosed |
| EP-2644595-A1 | N-Cyclylamides as nematicides | Syngenta Participations AG. (CH) | 2013-10-02 | — | — | EP | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| CN-101652383-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2013-09-18 | — | — | CN | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| CN-101821267-B | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2606038-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
| CN-101541784-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2013-04-24 | — | — | CN | disclosed |
| EP-2576510-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| CN-102971291-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2013-03-13 | — | — | CN | disclosed |
| EP-2565182-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20130023563-A1 | AMIDINOANILINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2545046-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120330019-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-27 | — | — | US | disclosed |
| EP-2118108-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| CN-1832929-B | 2, 4-pyrimidinediamines for the treatment of neoplastic diseases, inflammatory diseases and immune system disorders | NOVARTIS AG | 2012-11-07 | — | — | CN | disclosed |
| EP-2518054-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| CN-102711476-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| EP-2118110-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8227506-B2 | Benzamidine compound | AJINOMOTO., INC. (JP) | 2012-07-24 | — | — | US | disclosed |
| EP-1863793-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1863793-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| CN-101568336-B | Use of macrocyclic peptides for the preparation of hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-07-04 | — | — | CN | disclosed |
| CN-101568543-B | Macrocyclic peptides as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-06-06 | — | — | CN | disclosed |
| EP-2033654-B1 | Process for resolving a mixture of alkyl ester enantiomers using an enzyme | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2033654-B1 | Process for resolving a mixture of alkyl ester enantiomers using an enzyme | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8143243-B2 | 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| CN-102388045-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2012-03-21 | — | — | CN | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012024373-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-2086995-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2086995-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| EP-2396329-A1 | Compounds for the treatment of hepatitis c | Bristol-Myers Squibb Company (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011153509-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-2209789-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2209789-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1879910-B1 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1879910-B1 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-09 | — | — | EP | disclosed |
| CN-102239152-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2011-11-09 | — | — | CN | disclosed |
| WO-2011059239-A3 | METHODS AND APPARATUS TO SUPPORT RECONFIGURATION IN SELF ORGANIZED WIRELESS COMMUNICATIONS AND NETWORKS | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-7994202-B2 | Bicyclic nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2349260-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| CN-101076519-B | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL IND LTD | 2011-07-20 | — | — | CN | disclosed |
| US-20110172416-A1 | AMIDINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2340830-A2 | Hepatitis C Virus Inhibitors | Bristol-Myers Squibb Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-2340830-A2 | Hepatitis C Virus Inhibitors | Bristol-Myers Squibb Company (US) | 2011-07-06 | — | — | EP | disclosed |
| CN-102112486-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-06-29 | — | — | CN | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1455809-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1455809-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7960392-B2 | Nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-102083792-A | Compounds comprising a cyclobutoxy group | UCB PHARMA SA | 2011-06-01 | — | — | CN | disclosed |
| US-7935670-B2 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl- N-(1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)carboxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935670-B2 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl- N-(1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)carboxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935670-B2 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl- N-(1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)carboxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2314587-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2311810-A1 | AMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2300490-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1506172-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1506172-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7915291-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915291-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915291-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2298767-A1 | NITROGENATED BICYCLIC HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| CN-101228180-B | Tripeptides as hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-03-09 | — | — | CN | disclosed |
| US-7888464-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888464-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888464-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2089020-B1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2086980-B1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2086980-B1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-22 | — | — | EP | disclosed |
| CN-101925606-A | Compounds comprising a cyclobutoxy group | UCB PHARMA SA | 2010-12-22 | — | — | CN | disclosed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| CN-101821267-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2010-09-01 | — | — | CN | disclosed |
| WO-2010093359-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-19 | — | — | WO | disclosed |
| CN-101024671-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2010-08-18 | — | — | CN | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772183-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772183-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772183-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2209789-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| CN-1974596-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2010-07-28 | — | — | CN | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2183252-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| CN-101663290-A | The histamine H that comprises cyclobutoxy group 3Receptors ligand | UCB PHARMA SA | 2010-03-03 | — | — | CN | disclosed |
| CN-101652383-A | Hepatitis c virus inhibitors | SQUIBB BRISTOL MYERS CO US | 2010-02-17 | — | — | CN | disclosed |
| CN-101646667-A | Hepatitis C virus inhibitors | SQUIBB BRISTOL MYERS CO US | 2010-02-10 | — | — | CN | disclosed |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7652004-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009146347-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| CN-101583611-A | Inhibitors of hepatitis C virus | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | CN | disclosed |
| US-7618984-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| CN-101578294-A | Inhibitors of hepatitis C virus | BRISTOL MYERS SQUIBB CO (US) | 2009-11-11 | — | — | CN | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090275561-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| CN-101568336-A | Macrocyclic peptides as hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-101568543-A | Macrocyclic peptides as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-28 | — | — | CN | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| CN-101541784-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-09-23 | — | — | CN | disclosed |
| US-7592336-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592336-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592336-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| EP-2089385-A2 | INHIBITORS OF HEPATITIS C VIRUS | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2089020-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2086963-A2 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086995-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086994-A2 | INHIBITORS OF HEPATITIS C VIRUS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086967-A2 | INHIBITORS OF HEPATITIS C VIRUS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086980-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1684787-A4 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-7547690-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547690-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2009067108-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067108-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| EP-2049474-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| EP-2033654-A1 | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus | Bristol-Myers Squibb Company (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033654-A1 | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus | Bristol-Myers Squibb Company (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1629000-B1 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1629000-B1 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1505963-A4 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-24 | — | — | EP | disclosed |
| CN-101316841-A | Arylmethylene urea derivative and use thereof | TORAY INDUSTRIES (JP) | 2008-12-03 | — | — | CN | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112851-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951743-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1945641-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-23 | — | — | EP | disclosed |
| CN-101228180-A | Tripeptides as hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-07-23 | — | — | CN | disclosed |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-03 | — | — | US | disclosed |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-03 | — | — | US | disclosed |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-03 | — | — | US | disclosed |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | disclosed |
| CN-100391967-C | Hepatitis C tripeptide inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | CN | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| WO-2008064066-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064057-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064061-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| CN-101189223-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-05-28 | — | — | CN | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| WO-2008057875-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057875-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057873-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057871-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057871-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057873-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| EP-1904516-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO. INC (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1879910-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008008776-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| EP-1863793-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1847527-A1 | NOVEL BENZAMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| CN-101024671-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
| WO-2007084595-A2 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-7244692-B2 | Substituted benzoylcyclohexane diones for use as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2007-07-17 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| CN-1984908-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-06-20 | — | — | CN | disclosed |
| CN-1974596-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-06-06 | — | — | CN | disclosed |
| WO-2007056120-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056120-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| WO-2007044933-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| CN-1938311-A | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1758863-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | AstraZeneca AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| CN-1299677-C | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-02-14 | — | — | CN | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2007008657-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008657-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010455-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-11 | — | — | US | disclosed |
| US-20070010455-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-11 | — | — | US | disclosed |
| US-20070010455-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-11 | — | — | US | disclosed |
| US-20060293343-A1 | Pyrimidine derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1629000-A4 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060257980-A1 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-16 | — | — | US | disclosed |
| WO-2006122188-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006122188-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| US-7135462-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| CN-1832929-A | 2, 4-pyrimidinediamines for the treatment of neoplastic diseases, inflammatory diseases and immune system disorders | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060183694-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-17 | — | — | US | disclosed |
| US-20060172950-A1 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | WANG XIANGDONG A | 2006-08-03 | — | — | US | disclosed |
| EP-1684787-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1337550-B1 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| US-7041698-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1506172-A4 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1629000-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6995174-B2 | for inhibiting proteases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050267040-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1668297-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-09-14 | — | — | CN | disclosed |
| WO-2005051410-A9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005051410-A9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005051410-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6872805-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20050054534-A1 | Substituted benzoylcyclohexane diones for use as herbicides | MULLER KLAUS-HELMUT (DE) | 2005-03-10 | — | — | US | disclosed |
| EP-0906291-B1 | SUBSTITUTED PHENYL URACILS | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1506172-A2 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6825183-B2 | CONTROLLING PLANTS; ANTIGROWTH AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-30 | — | — | US | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| CN-1531547-A | Hepatitis C tripeptide inhibitors | ж� | 2004-09-22 | — | — | CN | disclosed |
| EP-1455809-A2 | INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004032827-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1244634-B1 | SUBSTITUTED BENZOYLCYCLOHEXANE DIONES FOR USE AS HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20040048802-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1337550-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030119674-A1 | Substituted benzoylcyclohexane diones for use as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6437126-B1 | HERBICIDES; REACTING 1-(4-CYANO-2-FLUORO-5-FORMYL-PHENYL) -3,6-DIHYDRO-2,6-DIOXO-3-METHYL-4-TRIFLUOROMETHYL-1(2H)-PYRIMIDINE WITH METHYOXYAMINE, AN AMINE, MERCAPTAN, OR AN ALCOHOL | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| WO-2002060926-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6245714-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |